Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Does the Reduction of Total Body Iron Storage (TBIS) Alter Mortality in a Population of Patients With Advanced PVD? (FeAST)
This study has been completed.
Sponsored by: Department of Veterans Affairs
Information provided by: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00032357
  Purpose

This study has successfully completed the feasibility phase. Forty-seven patients were enrolled at two sites. The results of the preliminary data indicated that the volumes of blood donated and the frequency of donation were well accepted by patients and safe. It also indicated that the formula for calculating volumes of blood to be removed to achieve the targeted reduction in Total Body Iron Stores (TBIS) was accurate and representative of the ferritin equivalence in storage iron found by others could be achieved.


Condition Intervention Phase
Atherosclerosis
Intermittent Claudication
Peripheral Vascular Diseases
Procedure: Ferritin reduction to 25 ng/ml by phlebotomy
Phase III

MedlinePlus related topics: Peripheral Arterial Disease Vascular Diseases
Drug Information available for: Ferritin
U.S. FDA Resources
Study Type: Interventional
Study Design: Diagnostic, Randomized, Single Blind (Outcomes Assessor), Active Control, Safety/Efficacy Study
Official Title: CSP # - 410, The Iron (Fe) and Atherosclerosis Study (FeAST)

Further study details as provided by Department of Veterans Affairs:

Estimated Enrollment: 1600
Study Start Date: May 1999
Study Completion Date: September 2005
Primary Completion Date: April 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1 Procedure: Ferritin reduction to 25 ng/ml by phlebotomy

Detailed Description:

Intervention: Ferritin reduction to 25 ng/ml by phlebotomy every 6 months vs placebo.

Minimum follow-up for each patient is 2.5 years.

Primary Hypothesis: Reduction of Total Body Iron Storage(TBIS) to a ferritin equivalent of approximately 25 ng/ml will alter mortality in a population of patients with advanced PVD.

Secondary Hypothesis: Reduction of TBIS to the same ferritin level will alter vascular disease morbidity in the same PVD patients population.

Primary Outcomes: Primary endpoint is mortality. Secondary endpoints include rates of non-fatal myocardial infarction and stroke, and the need for vascular intervention procedures.

Study Abstract: This study has successfully completed the feasibility phase. Forty-seven patients were enrolled at two sites. The results of the preliminary data indicated that the volumes of blood donated and the frequency of donation were well accepted by patients and safe. It also indicated that the formula for calculating volumes of blood to be removed to achieve the targeted reduction in Total Body Iron Stores (TBIS) was accurate and representative of the ferritin equivalence in storage iron found by others could be achieved.

This full study will last for six years. There will be 3.5 years of enrollment and a minimum of 2.5 years of follow-up for all study patients. It will involve a total of 1600 patients being recruited currently at 23 sites. Study patients will be seen every six months. Patients randomized to the ferritin reduction group will be monitored and have blood drawn to reach their targeted level of ferritin reduction of 25 ng/ml. The entry criteria will be the same as the feasibility study; however, the way patients will be stratified has changed. In the feasibility study, patients were stratified on the basis of their LDL/HDL ratios only. In this full study patients will be stratified on the basis of their entry LDL/HDL ratios as well as site, age, baseline ferritin level, smoking and diabetes status. Should the hypothesis of this study be confirmed, the results stand to have a considerable impact on health care delivery and cost of care.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Patients with Peripheral Vascular Disease

Exclusion Criteria:

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00032357

  Show 24 Study Locations
Sponsors and Collaborators
Investigators
Study Chair: Zacharski R. Leo VA Medical & Regional Office Center, White River
  More Information

Publications indexed to this study:
Responsible Party: Department of Veterans Affairs ( Leo, Zacharski - Study Chair )
Study ID Numbers: 410
Study First Received: March 19, 2002
Last Updated: October 8, 2008
ClinicalTrials.gov Identifier: NCT00032357  
Health Authority: United States: Federal Government

Keywords provided by Department of Veterans Affairs:
Ferritin reduction
Peripheral Vascular Disease (PVD)
phlebotomy
Reduction of Total Body Iron Storage(TBIS)
Total Body Iron Storage(TBIS)

Study placed in the following topic categories:
Arterial Occlusive Diseases
Atherosclerosis
Signs and Symptoms
Peripheral Vascular Diseases
Vascular Diseases
Intermittent Claudication
Arteriosclerosis
Iron

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009